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Blood glucose levels are tightly controlled by the two pep-
tide hormones glucagon and insulin. At hyperglycaemia,
B-cells in the islets of Langerhans secrete insulin, whereas
islet A-cells release glucagon at hypoglycaemia to stimu-
late e.g. glucose production in the liver. Previously, an
important role for nitric oxide (NO) in the development
of type-1 diabetes mellitus (insulin dependent diabetes
mellitus) was reported [1]. The mechanisms are unknown
whereby NO modulates islet (mal-)function. We hypoth-
esized that NO signals via the cGMP/cGMP kinase I
(cGKI) pathway to modulate the endocrine control of
blood glucose levels. Glucose homeostasis was studied in
the conventional cGKI knockouts (KOs) and in cGKI res-
cue mice (RM) [2] in comparison to age- and littermate
controls. The cGKI mutant mice were significantly hyper-
glycemic at fasting. Further in vivo analysis of RM revealed
no changes of the serum insulin levels, but the serum glu-
cagon was significantly increased in comparison to con-
trols. We anticipated that endogenous cGKI could directly
affect the release of glucagon, because immunofluores-
cence of Langerhans islets demonstrated that the cGKI
protein localized mainly to the glucagon-secreting A-cells
in control mice, but was absent from B-cells and not
detectable in the islets of gene-targeted cGKI mice. The
essential beta subunit of the soluble guanylyl cyclase
(sGCβ1) [3] and the cGMP-degrading phosphodiesterase-
5 (PDE-5), both important cGMP signaling components
in many cells, were also detectable in A-cells of all geno-
types analyzed. To identify a specific function for the path-
way in A-cells, we measured the hormone output of
isolated islets at physiologically low (6 mM) and high (20
mM) concentrations of glucose. Interestingly, the glucose-
induced suppression of glucagon release was abolished in
islets that lacked cGKI, whereas the total glucagon content
of the islets was not changed.
Taken together, our approach identifies a new function of
the cGMP-cGKI signaling pathway in pancreatic A-cells.
The genetic disruption of islet cGKI results in an abnormal
release of glucagon, which leads to a hyperglycaemic fast-
ing phenotype indicative for a pre-diabetic syndrome.
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